Overview

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given for leukemia in small fat-based particles (liposomes) to improve the drug getting into cancer cells. Giving ruxolitinib and CPX-351 may work better in treating patients with secondary acute myeloid leukemia compared to CPX-351 alone.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

OHSU Knight Cancer Institute
Uma Borate

Collaborators:

Incyte Corporation
Jazz Pharmaceuticals
National Cancer Institute (NCI)
Oregon Health and Science University

Treatments:

Cytarabine
Daunorubicin
Janus Kinase Inhibitors